Citius Pharmaceuticals, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Citius Oncology (majority-owned subsidiary of Citius Pharmaceuticals, $11.4M market cap) reported Q2 2026 commercial momentum for LYMPHIR (denileukin diftitox-cxdl): new institutional accounts ordering the drug increased 78% quarter-over-quarter; total institutional vial orders rose 31%; the drug is now available in 42 institutions with near-universal payer coverage; management targets formulary inclusion at 100 priority institutions by year-end. The initial CTCL market is estimated at >$400M. Revenue is recognized upon wholesale orders.
Why this rating
Early-stage commercial traction (78% QoQ growth, 42 institutions, payer coverage) for newly launched (Dec 2025) product in $400M+ market is material for micro-cap ($11.4M). However, early-stage revenue recognition via wholesale orders and execution risks remain.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.